June 2019 - Volume 3 - Issue S1 - Contributor Index

Author:
Iaccarino, S.

S1620 NELARABINE AS SALVAGE THERAPY AND BRIDGE TO ALLOGENEIC STEM CELLS TRANSPLANTATION IN 118 ADULT PATIENTS WITH RELAPSED/REFRACTORY T-ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA. A CAMPUS-ALL, PHASE 4, STUDY.

Candoni, A.; Lazzarotto, D.; Curti, A.; More

HemaSphere. 3(S1):748, June 2019.

Author:
Iacoboni, G.
Author:
Iacobucci, I.

PS997 A NEW BIOMARKER OF RESPONSE TO 5-AZACITIDINE THERAPY IN MDS AND AML PATIENTS: SIRPB1

Cerchione, C.; Guadagnuolo, V.; Papayannidis, C.; More

HemaSphere. 3(S1):448-449, June 2019.

Author:
Iannitto, E.

PF474 RETROSPECTIVE REAL-LIFE STUDY OF BRENTUXIMAB VEDOTIN IN ASSOCIATION WITH BENDAMUSTINE IN REFRACTORY OR MULTIPLE RELAPSED HODGKIN LYMPHOMA

Iannitto, E.; Romano, A.; Scalzulli, P.R.; More

HemaSphere. 3(S1):188-189, June 2019.

PF757 REDUCED INTENSITY CONDITIONING AND AVOIDING USE OF BROAD SPECTRUM ANTIBIOTHERAPY ACTIVE AGAINST GRAM-NEGATIVE BACTERIA MIGHT HAVE A CUMULATIVE IMPACT IN REDUCING INTESTINAL MICROBIOTA MISBALANCE

Espigado, I.; Rodriguez, N.; Labrador, G.; More

HemaSphere. 3(S1):332-333, June 2019.

Author:
Ibarra, M.

PS1581 COMPLEMENT SYSTEM ANALYSES IN PATIENTS SUSPECTED TO HAVE ATYPICAL HEMOLYTIC UREMIC SYNDROME

Nieto, J.M.; Perez-Avila, C. Cuellar; Fernandez, F.A. Gonzalez; More

HemaSphere. 3(S1):728-729, June 2019.

Author:
Ibatici, A.

PF375 IBRUTINIB AND RITUXIMAB AS FRONT-LINE TREATMENT FOR UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). PRELIMINARY RESULTS FROM THE GIMEMA LLC1114 STUDY

Mauro, F.R.; Molica, S.; Paoloni, F.; More

HemaSphere. 3(S1):139, June 2019.

PS1152 THE USE OF THE BCL-2 INHIBITOR IN CLL PATIENTS WHO PROGRESSED AFTER B-CELL-RECEPTOR INHIBITORS: A RETROSPECTIVE MULTICENTER ITALIAN EXPERIENCE

Innocenti, I.; Morelli, F.; Autore, F.; More

HemaSphere. 3(S1):522-523, June 2019.

Author:
Iberl, S.

S139 JUNCTIONAL ADHESION MOLECULE A (JAM-A) IS A CRITICAL REGULATOR OF HSC HOMING AND MAINTENANCE OF STEM CELL QUIESCENCE

Cao, B.; Hart, C.; Iberl, S.; More

HemaSphere. 3(S1):21, June 2019.

Author:
Ibrahiem, G.A.
Author:
ibrahim, M.A.

PF519 MOLECULAR PROFILING OF PRIMARY BONE LYMPHOMA'S REVEALS FREQUENT MUTATIONS IN EZH2 AND OTHER EPIGENETIC GENES: IMPLICATIONS FOR TARGETED TREATMENT

Ibramoglu*, M. Suleiman; de Groen*, R.A.; van Eijk, R.; More

HemaSphere. 3(S1):212, June 2019.

Author:
Ichikawa, S.

PF348 LONG TERM FOLLOW-UP OF PNH PATIENTS TREATED WITH THE SMART ANTI-HC5 ANTIBODY (SKY59/RO7112689) IN THE OPEN LABEL EXTENSION (OLE) OF THE COMPOSER TRIAL

Röth, A.; Nagy, Z.; Peffault de Latour, R.; More

HemaSphere. 3(S1):125-126, June 2019.

Author:
Ichiki, T.
Author:
Ichinohe, T.

S118 IMPACT OF PRE-TRANSPLANT DONOR-SPECIFIC ANTI-HLA ANTIBODIES IN CORD BLOOD TRANSPLANTATION ON BEHALF OF THE TRANSPLANT COMPLICATIONS WORKING GROUP OF JSHCT

Fuji, S.; Oshima, K.; Ohashi, K.; More

HemaSphere. 3(S1):11, June 2019.

Author:
Idowu, M.

S853 SUCCESSOR: A MULTICENTER RETROSPECTIVE NONINTERVENTIONAL FOLLOW-UP STUDY IN PATIENTS WITH SICKLE CELL PAIN CRISES WHO PREVIOUSLY PARTICIPATED IN THE SUSTAIN TRIAL IN THE UNITED STATES

Liles, D.; Shah, N.; Scullin, B.; More

HemaSphere. 3(S1):380-381, June 2019.

Author:
idris, N.
Author:
Idrissova, E.
Author:
Idrobo, H.

PB2124 OVERALL SURVIVAL OF MULTIPLE MYELOMA (MM) PATIENTS IN COLOMBIA: REPORT OF THE COLOMBIAN REGISTRY FOR HEMATO-ONCOLOGICAL DISEASES (RENEHOC) ASOCIACIÓN COLOMBIANA DE HEMATOLOGÍA Y ONCOLOGÍA (ACHO)

Melo, C. Sossa; Abello, V.; Idrobo, H.; More

HemaSphere. 3(S1):956-957, June 2019.

Author:
Ifrah, N.
Author:
Igarashi, T.

PF184 EFFICACY OF CONSOLIDATION CHEMOTHERAPY FOR PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WHO ACHIEVED COMPLETE REMISSION BY FIRST COURSE OF REMISSION INDUCTION THERAPY

Shigematsu, A.; Ota, S.; Kobayashi, R.; More

HemaSphere. 3(S1):44, June 2019.

Author:
Iglesias, T.

S113 GENETICS AND MODELING OF HUMAN ACUTE ERYTHROID LEUKEMIA

Fagnan, A.; Riera Piqué Borràs, M.; Ignacimouttou, C.; More

HemaSphere. 3(S1):8-9, June 2019.

PF151 RAS/MAPK ACTIVATION COOPERATES WITH GAIN OF CHROMOSOME 21 IN B CELL LEUKEMIA AND IS AN ATTRACTIVE TARGET TO IMPROVE THE OUTCOME OF DS CHILDREN WITH B-ALL

Laurent, A.P.; Siret, A.; Ignacimouttou, C.; More

HemaSphere. 3(S1):28, June 2019.

Author:
Ignatieva, S.

PS1285 INVASIVE FUNGAL DISEASES IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS WITH HODGKIN'S LYMPHOMA

Popova, M.; Rogacheva, Y.; Volkova, A.; More

HemaSphere. 3(S1):588, June 2019.

Author:
Ignatyeva, S.
Author:
Iida, S.

PF591 EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (D-RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF POLLUX BASED ON CYTOGENETIC RISK

Dimopoulos, M.A.; San-Miguel, J.; White, D.; More

HemaSphere. 3(S1):247-248, June 2019.

PF623 PHASE 1/2 STUDY OF ISATUXIMAB MONOTHERAPY FOR RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA IN JAPANESE PATIENTS

Iida, S.; Sunami, K.; Ri, M.; More

HemaSphere. 3(S1):265, June 2019.

S823 RANDOMIZED, OPEN-LABEL, NON-INFERIORITY, PHASE 3 STUDY OF SUBCUTANEOUS (SC) VERSUS INTRAVENOUS (IV) DARATUMUMAB (DARA) ADMINISTRATION IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: COLUMBA

Mateos, M.-V.; Nahi, H.; Legiec, W.; More

HemaSphere. 3(S1):364, June 2019.

PS1367 COMPREHENSIVE GENETIC ANALYSIS OF MULTIPLE MYELOMA IN JAPAN

Kanamori, T.; Sanada, M.; Ri, M.; More

HemaSphere. 3(S1):624-625, June 2019.

Author:
III, H. Adams
Author:
Iino, M.

PS1263 CONSOLIDATION THERAPY USING 90Y-IBRITUMOMAB TIUXETAN AFTER BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA; A MULTICENTER, PHASE II STUDY (BRIZ2012)

Tsujimura, H.; Miura, K.; Kanno, M.; More

HemaSphere. 3(S1):578, June 2019.

Author:
Iizuka, K.

PB2055 HIGH PREVALENCE OF NON-GERMINAL CENTER B-CELL PHENOTYPE WITH MYC OVEREXPRESSION IN JAPANESE PATIENTS WITH INTRAVASCULAR LARGE B-CELL LYMPHOMA

Takahashi, H.; Nakanishi, Y.; Miura, K.; More

HemaSphere. 3(S1):927, June 2019.

Author:
Iizuka, Y.
Author:
Ijurko, C.
Author:
Ikebe, E.
Author:
Ikeda, A.

S853 SUCCESSOR: A MULTICENTER RETROSPECTIVE NONINTERVENTIONAL FOLLOW-UP STUDY IN PATIENTS WITH SICKLE CELL PAIN CRISES WHO PREVIOUSLY PARTICIPATED IN THE SUSTAIN TRIAL IN THE UNITED STATES

Liles, D.; Shah, N.; Scullin, B.; More

HemaSphere. 3(S1):380-381, June 2019.

Author:
Ikeda, K.

PF407 TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA FOLLOWING FIRST-LINE DASATINIB, 1ST DADI/IMIDAS4

Murai, K.; Kimura, S.; Imagawa, J.; More

HemaSphere. 3(S1):155-156, June 2019.

Author:
Ikeda, T.

PF623 PHASE 1/2 STUDY OF ISATUXIMAB MONOTHERAPY FOR RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA IN JAPANESE PATIENTS

Iida, S.; Sunami, K.; Ri, M.; More

HemaSphere. 3(S1):265, June 2019.

Author:
Ikezoe, T.

PF407 TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA FOLLOWING FIRST-LINE DASATINIB, 1ST DADI/IMIDAS4

Murai, K.; Kimura, S.; Imagawa, J.; More

HemaSphere. 3(S1):155-156, June 2019.

PS1115 THE RELATIONSHIP BETWEEN THE PRETREATMENT PNH CLONE SIZE AND CLINICAL COURSE IN PATIENTS WITH BONE MARROW FAILURE SYNDROMES: INTERIM ANALYSIS OF JAPANESE MULTICENTER PROSPECTIVE STUDY

Ueda, Y.; Hosokawa, K.; Ishiyama, K.; More

HemaSphere. 3(S1):504-505, June 2019.

Author:
Ikuta, K.
Author:
Iland, H.

PS1028 ALLG APML5: A COMPARATIVE BIOAVAILABILITY STUDY OF ENCAPSULATED ORAL ARSENIC TRIOXIDE AND INTRAVENOUS ARSENIC TRIOXIDE IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA UNDERGOING CONSOLIDATION THERAPY

Iland, H.; Reynolds, J.; Boddy, A.; More

HemaSphere. 3(S1):463-464, June 2019.

Author:
Ilari, C.

PF365 PROGNOSTIC IMPLICATIONS OF IGHV GENE REARRANGEMENTS WITH “BORDERLINE” PERCENTAGE OF MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS

Raponi, S.; Ilari, C.; Della Starza, I.; More

HemaSphere. 3(S1):134-135, June 2019.

Author:
Ilariucci, F.

PF375 IBRUTINIB AND RITUXIMAB AS FRONT-LINE TREATMENT FOR UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). PRELIMINARY RESULTS FROM THE GIMEMA LLC1114 STUDY

Mauro, F.R.; Molica, S.; Paoloni, F.; More

HemaSphere. 3(S1):139, June 2019.

Author:
Ilhan, O.

PB1933 CLINICAL FEATURES AND TREATMENT OUTCOMES OF CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA PATIENTS IN TURKEY: REAL-WORLD DATA

Saydam, G.; Ünal, A.; Kurtoglu, E.; More

HemaSphere. 3(S1):879, June 2019.

Author:
Iliakis, T.

PS1192 INITIAL REPORT OF A NILOTINIB DISCONTINUATION PROJECT WITH 54 GREEK CML PATIENTS FOLLOWED IN ACCORDANCE TO THE APPROVED DISCONTINUATION INDICATION OF THE DRUG

Dimou, M.; Roumelioti, M.; Touloumenidou, T.; More

HemaSphere. 3(S1):543, June 2019.

PS1258 CLONAL B-CELL LYMPHOCYTOSIS OF MARGINAL ZONE ORIGIN (CBL-MZ): CLINICAL SIGNIFICANCE OF ABSOLUTE CLONAL B CELL COUNTS

Kalpadakis, C.; Pangalis, G.; Konstantinou, I.; More

HemaSphere. 3(S1):575, June 2019.

Author:
Ilic, I.

PB2175 LONG TERM FOLLOW-UP OF MAINTENANCE THERAPY WITH INTEREFRON ALPHA AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT IN MULTIPLE MYELOMA PATIENTS–SINGLE CENTER EXPERIENCE

Batinic, J.; Bašic-Kinda, S.; Pulanic, D.; More

HemaSphere. 3(S1):976, June 2019.

Author:
Ilieva, M.
Author:
Illert, A.L.
Author:
Illes, A.

S820 FRONTLINE BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY FOR STAGE 3/4 CLASSICAL HODGKIN LYMPHOMA: 3-YEAR UPDATE OF THE ECHELON-1 STUDY

Gallamini, A.; Straus, D.; Dlugosz-Danecka, M.; More

HemaSphere. 3(S1):362-363, June 2019.

PS1070 THE ECHELON-2 TRIAL: RESULTS OF A RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY OF BRENTUXIMAB VEDOTIN AND CHP (A+CHP) VERSUS CHOP IN FRONTLINE TREATMENT OF PATIENTS WITH CD30+ PERIPHERAL T-CELL LYMPHOMAS

Illidge, T.; Pro, B.; Trümper, L.; More

HemaSphere. 3(S1):484-485, June 2019.

PS1457 MAINTENANCE OF RESPONSE IN LONG-TERM TREATMENT WITH ROPEGINTERFERON ALFA-2B (BESREMI®) VS. HYDROXYUREA IN POLYCYTHEMIA VERA PATIENTS (PROUD/CONTINUATION-PV PHASE III TRIALS)

Gisslinger, H.; Klade, C.; Georgiev, P.; More

HemaSphere. 3(S1):670-671, June 2019.

Author:
Illés, Á.

PF294 IMPROVED OUTCOMES IN PATIENTS (PTS) WITH BCL2-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH VENETOCLAX (VEN) PLUS R-CHOP: RESULTS FROM THE PHASE 2 CAVALLI STUDY

Morschhauser, F.; Feugier, P.; Flinn, I.W.; More

HemaSphere. 3(S1):99, June 2019.

PS1157 EFFECT OF DOSE MODIFICATIONS ON RESPONSE TO DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY CLL/SLL IN THE DUO TRIAL

Ghia, P.; Flinn, I.; Lamanna, N.; More

HemaSphere. 3(S1):525, June 2019.

Author:
Illidge, T.

PS1070 THE ECHELON-2 TRIAL: RESULTS OF A RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY OF BRENTUXIMAB VEDOTIN AND CHP (A+CHP) VERSUS CHOP IN FRONTLINE TREATMENT OF PATIENTS WITH CD30+ PERIPHERAL T-CELL LYMPHOMAS

Illidge, T.; Pro, B.; Trümper, L.; More

HemaSphere. 3(S1):484-485, June 2019.

PS1256 CONTEMPORARY TREATMENT PATTERNS AND RESPONSE IN RELAPSE/REFRACTORY CUTANEOUS T-CELL LYMPHOMA (CTCL) IN CLINICAL PRACTICE IN FRANCE, GERMANY ITALY, SPAIN AND THE UNITED KINGDOM

Illidge, T.; Bagot, M.; Waser, N.; More

HemaSphere. 3(S1):573-574, June 2019.

Author:
Illig, T.

PS1326 IMPLEMENTATION OF FUNCTIONAL ASSAYS TO CHARACTERIZE AND DETERMINE THE CLINICAL IMPACT OF RUNX1 VARIANTS OF UNCERTAIN SIGNIFICANCE IN SPORADIC DISEASES AS WELL AS IN THE CONTEXT OF FPDMM

Decker, M.; Lammens, T.; Ferster, A.; More

HemaSphere. 3(S1):605, June 2019.

Author:
Illman, J.
Author:
Iltar, U.
Author:
Ilyasov, R.

PS1104 EPIDEMIOLOGICAL STUDY OF IDIOPATHIC THROMBOCYTOPENIC PURPURA AMONG THE ADULT POPULATION OF THE RUSSIAN FEDERATION

Melikyan, A.; Egorova, E.; Pustovaya, E.; More

HemaSphere. 3(S1):500, June 2019.

Author:
Im, J.

PS1530 POST-TRANSPLANT CYCLOPHOSPHAMIDE IN HLA MATCHED AND HAPLOIDENTICAL TRANSPLANT RECIPIENTS RECEIVING MYELOABLATIVE TIMED SEQUENTIAL BUSULFAN CONDITIONING REGIMEN: RESULTS OF A PHASE II STUDY

Mehta, R.; Bassett, R.; Olson, A.; More

HemaSphere. 3(S1):706, June 2019.